# US 2010/0169994 A1 · Animal model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0169994 A1
- Document ID: US20100169994A1
- Status: Published application
- Kind: A1
- Application number: 12/523,471
- Filed: 2008-01-17
- Published: 2010-07-01
- Earliest claimed: 2007-01-17
- Inventors: Susan Clare Stanford; Hugh Gurling; Steven Hunt
- Web page: https://patentgrep.com/patent/US20100169994A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/30: for treating abuse or dependence
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of a NK1−/− animal as a model for attention deficit hyperactivity disorder and related conditions, to markers for those conditions and to methods of treating such conditions.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3 (depends on 6, 7)

The method according to claim 6 or 7, wherein the animal is a non-human animal.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the animal is a rodent.

### Claim 5

A method for identifying a compound that affects ADHD, alcoholism, dyspraxia, conduct disorder, deliverate self-harm or -injury, or suicidality, comprising:
contacting a test compound with a cell, tissue, or organ from an NK1−/− animal or a NK1−/− cell or a tissue or organ made up of such cells and determining effects of the test compound.

### Claim 6

A method for identifying a compound that affects ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury, or suicidality comprising;
administering a test compound to a NK1−/− animal or to an animal treated with an antagonist to substance P receptor; and
determining effects on behavior of the animal.

### Claim 7

A method for identifying a compound that affects ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self harm or injury or suicidality comprising:
administering a test compound to a NK1−/− animal or to an animal treated with an antagonist to substance P receptor; and
determining changes in neurotransmitter function in brain of the animal.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein the effects on behavior or changes in neurotransmitter function are reductions in symptoms or signs of ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self harm or injury or suicidality.

### Claim 9

(canceled)

### Claim 10

A method of determining a predisposition of a subject to ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality, comprising:
identifying a polymorphism in an NK1 gene or a region flanking that gene in a sample obtained from that subject, wherein the polymorphism is a marker for ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality.

### Claim 11

A method of determining a predisposition of a subject to ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality, comprising:
identifying in a sample obtained from the subject a peptide encoded by, or an RNA molecule complementary to, an NK1−/− gene comprising a polymorphism, wherein the peptide is not encoded by, and the RNA molecule is not complementary to a wild-type NK1 gene, wherein the polymorphism is associated with ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality.

### Claim 12 (depends on 10, 11)

A method according to claim 10 or claim 11, wherein the sample is a sample of blood, tissue, brain, urine or saliva.

### Claim 13 (depends on 10)

A method of claim 10 wherein the subject is a human.

### Claim 14 (depends on 10)

The method of claim 10, wherein the polymorphism is a single nucleotide polymorphism.

### Claim 15 (depends on 14)

The method of claim 14, wherein the single nucleotide polymorphism is rs3771856.

### Claim 16 (depends on 10)

The method of claim 10 wherein the polymorphism is in the first intron of the NK1 gene.

### Claim 17 (depends on 16)

The method of claim 16, wherein the polymorphism is a single nucleotide polymorphism.

### Claim 18 (depends on 17)

The method of claim 17, wherein the single nucleotide polymorphism is rs3771856.

### Claim 19

A transgenic animal that comprises an exogenous NK1 gene.

### Claim 20 (depends on 19)

An animal according to claim 19, wherein the animal is a rodent.

### Claim 21 (depends on 20)

An animal according to claim 20, wherein the NK1 gene is a human NK1 gene.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

A method of treating ADHD, alcoholism, dyspraxia, conduct disorder, deliberate self-harm or -injury or suicidality, comprising:
administering a pharmaceutical composition comprising a vector comprising a wild-type NK1 gene to a subject in need thereof.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the subject has a polymorphism or mutation in the NK1 gene.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

A method of identifying a candidate compound for use in the treatment of ADHD, alcohol addiction, dyspraxia, conduct disorder, self-harm or -injury, or suicidality, comprising:
testing for
a compound that binds to a NK1 gene product, intracellular proteins or portions of proteins that interact with a NK1 gene product;
a compound that interferes with the interaction of a NK1 gene product with intracellular proteins; or
a compound that modulates level of NK1 gene expression and/or level of NK1 gene product activity; and
identifying the compound as a candidate for treating ADHD, alcohol addiction, dyspraxia, conduct disorder, self-harm or -injury, or suicidality.
